“As the dysfunction of the endocannabinoid
system becomes implicated in more diseases including migraine, irritable bowel,
fibromyalgia, epilepsy, and even menstrual cramps now add muscular dystrophy as
a potential area of interest for endocannabinoids. Jerry Lewis should be
smiling.”
-
Dr. David Hepburn
The
endocannabinoid system refers to a widespread signaling system and its
alterations implicated in a growing number of human diseases. However, the
potential role of endocannabinoids in skeletal muscle is ordered the main sun
is known.
In
murine and human models, CB1 transcripts how the highest degree of expression
at disease onset, and then decline over time. Similar changes are observed for
PAX7, a key regulator of muscle stem cells. Bioinformatics and biochemical
analysis revealed that PAX7 binds and upregulates the CB1 gene in dystrophic
more than in healthy muscles.
Rimonabant,
an antagonist of CB1, promotes human satellite cell differentiation in vitro,
increases the number of regenerated myofibers, and prevents locomotor
impairment in dystrophic mice. In conclusion, our study uncovers a PAX7–CB1
cross-talk potentially exacerbating DMD and highlights the role of CB1
receptors as target for potential therapies.
Read
full article here:
0 comments:
Post a Comment